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Abstract
Background: There is no consensus regarding optimal treatment for peripheral T-cell lymphomas (PTCL), especially in
relapsed or refractory cases, which have very poor prognosis and a dismal outcome, with 5-year overall survival of 30 %.
Methods: A multicenter prospective phase II trial was conducted to investigate the role of the combination of
gemcitabine plus romidepsin (GEMRO regimen) in relapsed/refractory PTCL, looking for a potential synergistic
effect of the two drugs. GEMRO regimen contemplates an induction with romidepsin plus gemcitabine for six
28-day cycles followed by maintenance with romidepsin for patients in at least partial remission. The primary
endpoint was the overall response rate (ORR); secondary endpoints were survival, duration of response, and
safety of the regimen.
Results: The ORR was 30 % (6/20) with 15 % (3) complete response (CR) rate. Two-year overall survival was
50 % and progression-free survival 11.2 %. Grade ≥3 adverse events were represented by thrombocytopenia
(60 %), neutropenia (50 %), and anemia (20 %). Two patients are still in CR with median response duration of
18 months. The majority of non-hematological toxicities were mild and transient. No treatment-related death
occurred and no toxicity led to treatment interruption.
Conclusions: GEMRO combination regimen shows efficacy data similar to those of single-agent romidepsin
with additional hematologic toxicities. Synergy observed in preclinical phase did not turn into ability to
improve clinical outcomes.
Trial registration: The trial was registered under EudraCT 2012-001404-38; ClinicalTrials.gov number,
NCT01822886.
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Background
Peripheral T-cell lymphomas (PTCL) comprise a heteroge-
neous group of lymphoid malignancies arising from ma-
ture T-cells which present with different phenotypes and
clinical presentations [1, 2]. These aggressive lymphomas
are uncommon, constituting 10–12 % of non-Hodgkin’s
lymphomas (NHL) in Western countries [3] but are rela-
tively common in Eastern Asian, constituting about 20 %
of mature NHL [4]. There is no consensus regarding opti-
mal treatment for PTCL, especially in relapsed or refrac-
tory cases, which have very poor prognosis. High-dose
chemotherapy followed by autologous stem cell transplant-
ation (ASCT) has been accepted as a salvage treatment for
eligible patients, although the evidence is unclear [5].
Moreover, the overall prognosis remains dismal in patients
unsuitable for ASCT. Thus, effective salvage chemotherapy
prior to ASCT or optimal therapeutic approach for pa-
tients ineligible for ASCT should be investigated in order
to improve the prognosis of PTCL patients. Despite the
enormous advances in our understanding of aggressive
lymphomas, it is clear that progress in PTCL management
has lagged well behind other B-cell malignancies. Over the
past 5 years, the US Food and Drug Administration (FDA)
has approved four drugs for patients with relapsed/refrac-
tory PTCL, and, counting the recent Japanese approval of
the anti-CCR4 monoclonal antibody for patients with adult
T-cell leukemia/lymphoma, five drugs have been approved
worldwide [6–10]. These approvals have led to the initi-
ation of no fewer than four randomized clinical studies, ex-
ploring the integration of these new agents into standard
CHOP (cyclophosphamide–adriamycin–vincristine–pred-
nisone)-based chemotherapy regimens for patients with
newly diagnosed PTCL [11–14]. In addition, new waves of
studies are exploring the potential benefits of novel drug
combinations, an effort to build on the obvious single-
agent successes. What has emerged most recently is the
recognition that PTCL may be a disease characterized by
epigenetic dysregulation: this could explain PTCL sensitiv-
ity to histone deacetylase (HDAC) inhibitors and open the
door for even more creative combination approaches.
Gemcitabine (2′,2′-difluorodeoxycytidine) is a pyrimi-
dine anti-metabolite with clinical activity in aggressive
lymphomas. The overall response rates (ORR) for gemci-
tabine as a single agent in relapsed/refractory PTCL are
up to 50 % [15, 16], while the single-agent activity is lower
in relapsed/refractory aggressive B-cell NHL with a re-
ported ORR of 20 % in small series [17]. Gemcitabine-
based combinations with other chemotherapeutic agents
afford higher response rates, although even toxicity occur-
rence is higher (especially myelosuppression and infective
complications) [18].
Romidepsin is an HDAC inhibitor that was approved by
FDA in 2011 for the treatment of PTCL in patients who
have received at least one prior therapy [7]. A larger, pivotal
phase II study on romidepsin in patients with relapsed or
refractory PTCL showed an overall response rate of 25 %
(complete response [CR] rate of 15 %) without significant
differences in response rates between patient subgroups
that included major PTCL subtypes [7]. On the basis of
these data, there are some trials examining the combination
of romidepsin with conventional chemotherapy regimens
[11, 19]. Currently, romidepsin is under investigation for
patients with PTCL in various combinations, i.e., aurora A
kinase inhibitor alisertib [20], proteasome inhibitors borte-
zomib [21], carfilzomib [22], lenalidomide [23, 24], and pra-
latrexate [25].
Starting from these data and due to the still unmet
clinical need for patients with relapsed/refractory PTCL,
we designed a multicenter phase II study to investigate
the role of the combination of gemcitabine plus romi-
depsin (GEMRO regimen) looking for a potential syner-
gistic effect of the two drugs.
Methods
Study population and eligibility criteria
Patients with histologically proven PTCL as per WHO cri-
teria and for whom previous treatments had failed were
eligible for this study. Additional inclusion criteria included
measurable disease, an absolute neutrophil count >1 × 109/
l, hemoglobin >8 g/dl, platelets >100 × 109/l, and normal
renal and hepatic functions. All patients had to have an
Eastern Cooperative Oncology Group performance status
(PS) score of 0–2 at time of enrolment. Patients had not to
have received prior gemcitabine or romidepsin therapy.
Study design
This was a phase II clinical study on patients with
PTCL conducted at 4 Italian centers. The local ethic
committee at each centre approved the study protocol
and its amendments, in accordance with the Italian
law and complying with the Declaration of Helsinki
(ethical committee of the coordinating center, Comitato
Etico Policlinico S. Orsola-Malpighi Bologna, Italy; refer-
ence number 045-2012/U). Patients provided written in-
formed consent before enrolment.
The dose and schedule of this combined regimen
were extrapolated by a phase I trial of romidepsin in
combination with gemcitabine in patients with pancre-
atic and other advanced solid tumors [26]. The present
phase II study included an induction part with romidepsin
12 mg/m2 i.v. on days 1, 8, and 15 and gemcitabine
800 mg/m2 i.v. on days 1 and 15 for 6 cycles, each cycle to
be repeated every 28 days. After this induction phase,
patients who obtained at least a partial response (PR) pro-
ceeded onto romidepsin maintenance at the dose of
14 mg/m2 i.v. until disease progression.
Clinical evaluations at the time of study entry included
medical history and physical examination, complete blood
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cell count, serum biochemistry, electrocardiogram and
echocardiogram, computed tomography (CT) scan of the
neck, chest, abdomen, and pelvis, and positron emission
tomography (PET) scan of the total body. Bone marrow
and lymph node biopsies had not to be if performed be-
fore signing the study informed consent as part of stand-
ard medical care within 56 days before GEMRO for bone
marrow biopsy and within 6 months for lymph node bi-
opsy, respectively.
Patient response was evaluated after 3 cycles of GEMRO
and 4 weeks after the end of the induction phase (i.e., after
the sixth cycle); in addition, during the maintenance phase
with romidepsin, the response evaluation was done every
4 months for the first 2 years. All sites of initial disease
were reassessed by CT scan, PET scan, and bone marrow
biopsy for patients who had bone marrow involvement.
Response assessment was performed according to the
Revised Response Criteria for Malignant Lymphoma [27].
The trial was registered under EudraCT 2012-001404-38;
ClinicalTrials.gov number, NCT01822886.
Statistical analysis
Sample size estimation was performed by Fleming’s
single-stage procedure. Defined p0 as the proportion of
response below which the treatment does not warrant
further investigations and pα as the proportion of re-
sponses beyond which a phase 3 trial should be carried
out, we set p0 = 0.3 and pα = 0.7. The number of patients
required, given a type I error at 0.05 one sided and a
power of 80 %, was 18 and the number of successes 13.
Taking into account a dropout of 10 %, the number of
patients was set at 20.
The primary endpoint of this study was ORR after the
induction phase, consisting of the sum of CR and PR rates;
the secondary endpoints were duration of the response,
progression-free survival (PFS), overall survival (OS), and
safety of the GEMRO regimen [27]. Survival curves were
estimated using the Kaplan-Meier method. For the safety
analyses, frequency of toxicities was reported by type and
grade according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (version 4.0).
Efficacy and safety were evaluated on the basis of
intention-to-treatment. All analyses were performed
using STATA (version 11.1).
Results
Patient characteristics
A total of 20 patients with relapsed/refractory PTCL
were enrolled and treated between January 2013 and
December 2014. The baseline characteristics of the patients
in this study are summarized in Table 1. The median age of
patients was 55 years (range 24–77 years), and 10 were
males (50 %). All patients had a good PS of 0 or 1. Re-
garding the histology, 10 (50 %) patients had PTCL not
otherwise specified (PTCL-NOS), 9 (45 %) patients had
angioimmunoblastic T-cell lymphoma (AITL), and 1 (5 %)
patient had anaplastic large cell lymphoma (ALCL) anaplas-
tic lymphoma kinase (ALK) negative. No follicular helper
T-cell cases were observed. One patient (5 %) was stage II,
and 19 patients (95 %) were stage III or IV. In addition,
there were 10 patients (50 %) with extranodal involvement,
6 of whom with bone marrow involvement. The 80 % of
subjects had an international prognostic index score ≥2. Pa-
tients had received a median of two (range, 1–4) prior
treatment regimens and 7 (35 %) of patients had failed prior
autologous stem cell transplantation. There were 12 refrac-
tory cases (60 %) and 8 relapsed cases (40 %).
Response to treatment and outcomes
Patients started GEMRO therapy at a median time from
diagnosis of 13.9 months. The median number of cycles
received per patient during induction phase was 3 (range
1–6). Six patients withdrew from treatment before the
first scheduled restaging due to objective clinical pro-
gression of the underlying disease.
At the end the induction phase, the ORR was 30 % (6/
20 patients) and included 3 (15 %) CR and 3 (15 %) PR;
among the remaining patients, stable disease was observed
Table 1 Patient characteristics
Characteristic Patients
n (%)
Age, years
Median 55
Range 24–77
Sex
Male 10 (50)
Female 10 (50)
Histology
PTCL-NOS 10 (50)
AITL 9 (45)
ALCL, ALK negative 1 (5)
Stage at enrolment
I–II 1 (5)
III–IV 19 (95)
Extranodal involvement 10 (50)
International Prognostic Index
≥2 16 (80)
No. of prior regimens
Median 2
Range 1–4
Refractory to most recent therapy 12 (60)
PTCL-NOS peripheral T-cell lymphoma not otherwise specified, AITL
angioimmunoblastic T-cell lymphoma, ALCL anaplastic large cell lymphoma, ALK
anaplastic lymphoma kinase
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in one (5 %) case and 13 (65 %) had progressive disease.
According to the histologic subsets, among the 6 re-
sponders, there were 4 PTCL-NOS (2 CR and 2 PR) and 2
AILT (1 CR and 1 PR). One (an AITL) of the 3 CR pa-
tients discontinued the treatment after 4 cycles due to car-
diologic problems not related to the therapeutic regimen,
and she is currently in CR after 35 months: Fig. 1 shows
the rapid and complete disappearance of the lymphoma
assessed by PET scan.
All the responders (CRs and PRs), except for the CR
patient who stopped the treatment after 4 cycles, under-
went maintenance phase with romidepsin. Current me-
dian number of cycles in the maintenance phase is 5,
but one patient is still on treatment (12th cycle).
During the maintenance period, two PRs had a disease
progression after 4 and 5 months, respectively; the third
PR patient, after 2 months of maintenance, underwent al-
lotransplant obtaining CR. At this time, 2/3 CRs are in
continuous response after 12 and 35 (AILT patient treated
with only 4 cycles) months, respectively. One CR patient
relapsed after the sixth cycle of maintenance. Median dur-
ation of response was 12.4 months, 18 months for CR
patients.
At a median follow-up of 18 months, the 2-year OS rate
for all patients was 50 % (median reached at 22 months,
Fig. 2), the 2-year PFS rate for all patients was 11.2 % with
median reached at 2.5 months (Fig. 3). At the latest
follow-up, 10 patients were deceased due to lymphoma
and 10 patients were still, 3 of whom without disease.
Safety
Treatment-related toxicities are shown in Table 2. The
most common grade 3 or 4 toxicity was thrombocytopenia,
which was observed in 12 patients (60 %); grade 3 or 4 neu-
tropenia was observed in 10 (50 %) patients while grade 3/4
anemia occurred in 20 % of cases. The majority of non-
hematological toxicities were mild and transient. There was
no grade 4 non-hematological toxicity observed in the
study; however, a grade 3 transaminase increase occurred
in 3 patients. No treatment-related death occurred and no
toxicity led to treatment interruption.
Discussion
The generally poor outcomes observed in PTCL patients
highlight the urgent need for alternative treatment strat-
egies. Several novel approaches have been evaluated in
single-arm phase I and II studies, mainly in patients with
relapsed/refractory disease, which has a particularly poor
prognosis. In a recent registry study [28], PTCL patients
receiving CHOP or CHOP-like regimens as first-line ther-
apy showed poor outcomes: 25 % of patients had refrac-
tory disease with a median OS of 2.5 months and 53 % of
Fig. 1 Clinical case: positron emission tomography results pre- (a) and post-therapy (b)
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responding patients relapsed with a median OS of
6 months. There is, consequently, a requirement for
effective second-line treatments for relapsed and refrac-
tory PTCL. Over recent years, several single-agent therap-
ies have proven to be effective in this setting. Pralatrexate,
romidepsin, and belinostat are all approved broadly for
PTCL with ORRs in large phase II studies of 29, 25, and
26 %, respectively [6, 7, 9]. Brentuximab vedotin is also ap-
proved in relapsed ALCL with an ORR of 86 % in a small
phase II trial [8]. In addition, mogamulizumab (approved
only in Japan) reported an ORR of 34 % in a small PTCL
phase II study [10].
Regarding the combination of romidepsin and gemci-
tabine, there were some interesting preclinical data in
solid tumors: romidepsin synergistically inhibits cell pro-
liferation with gemcitabine by suppressing removal of in-
corporated harmful nucleotide analogues of DNA [29].
Despite minimal clinical activity of this combination in
solid tumors [26], romidepsin plus gemcitabine is being
studied in several phase I trials underway in patients
with PTCL [30, 31].
In our study, we reported an ORR of 30 % with a CR
rate of 15 %. The median duration of response was
12 months (range, 9–35 months with median follow-up
of 18 months) and the median PFS was reached at
2.5 months. In responding patients, the achievement of
CR was associated with prolonged PFS and OS com-
pared with all other outcomes. The safety profile was
overall hematologic, and particularly it was represented
by thrombocytopenia and neutropenia.
The ORR and CR rates did not differ from data reported
on romidepsin as a single agent [7]. At the same time,
there was a similar outcome for responding patients as
observed in the pivotal phase II study on romidepsin in
monotherapy [32]. Remarkably, the median PFS was
analogous to those reported for PTCL after relapse or pro-
gression, regardless of the treatment, e.g., romidepsin or
belinostat [7, 9, 33]. On the other side, the toxicity profile
of GEMRO regimen reported additional hematologic tox-
icities, as previously stated in the phase I study on solid
tumors [26].
One possible reason for these disappointing results
could be that cases with extensive and refractory disease
were enrolled: 95 % of patients had stage III–IV disease
and 60 % patients were refractory. It could be important
to revise the GEMRO regimen on the basis of different
schedule (dose and timing) of both drugs.
Conclusions
We identified disappointing clinical results with GEMRO
plan in relapsed/refractory PTCL. In fact, these prelimin-
ary data failed to show a superiority of the GEMRO com-
bination regimen over single-agent romidepsin as salvage
treatment in this setting of patients. These data could in-
dicate that synergy observed in preclinical phase does not
always turn into ability to improve clinical outcomes. For
the next steps, potential modifications of the treatment
schedule are requested to allow more substantial delivery
of the treatment and subsequent better clinical response.
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Fig. 3 Progression-free survival
Table 2 Treatment-related adverse event: all events and
grade ≥3 events
Any grade Grades 3–4
N (%) N (%)
Anemia 12 (60) 4 (20)
Neutropenia 11 (55) 10 (50)
Thrombocytopenia 16 (80) 12 (60)
Febrile neutropenia 2 (10) 0
Nausea and vomiting 10 (50) 0
Pyrexia 6 (30) 0
Transaminase increase 4 (20) 3 (15)0 10 20 30 40
0
20
40
60
80
100
months
%
Fig. 2 Overall survival
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